Press-release for stocks for SNY

Prices are updated after-hours

FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
Published: 2021-03-04 (Crawled : 06:03) - globenewswire.com
SNY | News | $46.82 -1.82% 510K

| 3.52% | O: 1.21% H: 0.59% C: -0.24%
REGN | News | $911.73 0.49% 97K

| 103.1% | O: -0.3% H: 1.46% C: 0.9%
fda fda acceptance children dupixent

Sanofi launches recommended cash offer for all shares in Kiadis
Published: 2021-02-12 (Crawled : 06:03) - globenewswire.com
SNY | News | $46.82 -1.82% 510K

| -1.34% | O: -1.17% H: 1.08% C: 0.91%

54%

46%

CSSE 4 | $0.3499 129.74% 150M

CZOO | $11.04 121.24% 9.6M

BOF | $2.05 75.21% 78M

AMST | $3.2 60.0% 63M

LICN | $0.8592 53.43% 13M

WIMI | $1.05 44.75% 13M

TROO | $1.51 38.53% 5.6M

MULN | News | $3.675 34.62% 11M

RILY | $27.91 28.5% 8.9M

WHLM | $6.43 26.58% 580K

Save your searches and get alerts when important news are released.